New Legal Pathway for Biosimilars Creates Opportunities and Challenges For Biological Manufacturers — A Guide To The Legislation
14 June 2010
Foley Partners Jacqueline Wright Bonilla and Nathan Beaver authored an article that appeared in the June 2010 issue of Bloomberg’s Health Law Report titled “New Legal Pathway for Biosimilars Creates Opportunities and Challenges For Biological Manufacturers — A Guide To The Legislation.”
Author(s)
Related Insights
21 March 2025
IP Litigation Current
Federal Circuit Opens the Door to Additional Domestic Industry Investment: “Ordinary Importer” No Longer
In its recent decision in Lashify, Inc. v. International Trade Commission, the Federal Circuit opened the door for patent owners to include expanded categories of domestic investment to satisfy the economic prong of the domestic industry requirement under Section 337(a)(3)(B).
21 March 2025
Manufacturing Industry Advisor
Federal Court Rejects FCA’s “65%-100%” Language as Insufficient to Constitute the Necessary Quantity Term in a Requirements Contract—A Win for Suppliers
A recent federal court decision marks an important win for automotive suppliers in the ongoing debate over what constitutes a valid requirements contract under Michigan law following the Michigan Supreme Court’s decision in MSSN, Inc. v. Airboss Flexible Products Co. (2023).
27 April 2025
Events
Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value
Foley partner Kinal Patel is speaking at the 2025 National Proton Conference in a panel titled “Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value” on April 27.